anti-TRAILR2/CDH17 tetravalent bispecific antibody BI 905711

{
  "id": "MLC-T-ONC-011145",
  "term": "anti-TRAILR2/CDH17 tetravalent bispecific antibody BI 905711",
  "field": "Oncology and biomedicine",
  "definition": "A tetravalent bispecific antibody targeting both the pro-apoptotic death receptor tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2; death receptor 5; DR5) and cadherin-17 (CDH17), with potential pro-apoptotic and antineoplastic activities. Upon administration of anti-TRAILR2/CDH17 tetravalent bispecific antibody BI 905711, the antibody targets and binds to both TRAILR2 and CDH17, expressed on tumor cells. Receptor clustering and activation of TRAILR2 induces apoptosis in CDH17-positive cancer cells. Activation of TRAILR2 plays a key role in the induction of apoptosis. CDH17-dependent clustering of TRAILR2 allows BI 905711 to selectively induce apoptosis in CDH17-expressing tumor cells thereby increasing efficacy and decreasing liver toxicity. CDH17 is overexpressed in a variety of cancer cell types while its expression is restricted in normal liver tissue.",
  "synonyms": [
    "bi-specific agent BI 905711",
    "CDH17-targeting TRAILR2 agonist BI 905711"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-trailr2-cdh17-tetravalent-bispecific-antibody-bi-905711/"
}